Literature DB >> 19175784

A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis.

S Tabolli1, L Alessandroni, B Didona, C Di Pietro, P Gisondi, L Rota, F Sampogna, D Abeni.   

Abstract

BACKGROUND: The therapeutic effects of some histological staining agents on psoriasis have been reported in the past. One of these agents is eosin, which is still currently used in routine treatment, although it has never been formally tested in a randomized controlled trial. Aim. To compare treatment with eosin in patients with moderate to severe psoriasis vs. short-course topical steroid, a well-defined, evidence-based treatment.
METHODS: A randomized trial was designed and conducted. The Skindex-29 and General Health Questionnaire (GHQ)-12 questionnaires, and Psoriasis Activity and Disease Index (PASI) were used before treatment in 43 patients. Five days after treatment, PASI was measured again.
RESULTS: Five days after treatment, a significant mean reduction of PASI was observed in both groups: 6.8 (95% CI 5.5-8) for eosin, and 5.2 (3.2-7.1) for steroids. The difference between the two groups was not significant (P = 0.161).
CONCLUSIONS: Eosin has a short-term effect similar to topical steroids. The low cost of eosin treatment and its limited collateral effects suggest that eosin could be an effective steroid-sparing agent in the initial phase of psoriasis treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19175784     DOI: 10.1111/j.1365-2230.2008.02932.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  2 in total

1.  Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0).

Authors:  Qiongling Liu; Li Feng; Chonghua Wan; Jianfeng Tan; Jianbin Yu; Li Wang
Journal:  Health Qual Life Outcomes       Date:  2022-04-22       Impact factor: 3.077

2.  Effect of the most common wound antiseptics on human skin fibroblasts.

Authors:  Manuel Rueda-Fernández; Lucía Melguizo-Rodríguez; Víctor J Costela-Ruiz; Elvira de Luna-Bertos; Concepción Ruiz; Javier Ramos-Torrecillas; Rebeca Illescas-Montes
Journal:  Clin Exp Dermatol       Date:  2022-06-16       Impact factor: 4.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.